Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects

Cancer Research

Volumn 61, Issue 11, 2001, Pages 4497-4505

  Grosenbach, Douglas W ^a   Barrientos, Jacqueline C ^b   Schlom, Jeffrey ^a   Hodge, James W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; FEMALE; FOWLPOX VIRUS; GENE EXPRESSION; IMMUNE RESPONSE; LIVER METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TRANSGENE; TUMOR IMMUNITY; VACCINATION; VACCINIA VIRUS; VIRUS RECOMBINANT;

ANIMALS; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; T-LYMPHOCYTES;

EID: 0035360260     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Identification of human cancers deficient in antigen processing
2. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
3. + T cells: Efficacy is limited by migration away from the site and induction of nonresponsiveness
4. Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine
5. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus
6. + T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity
7. Adoptive immunotherapy as an in vivo model to explore antitumor mechanisms induced by a recombinant anticancer vaccine
8. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity
9. Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth
10. Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7
11. A recombinant vaccinia vires expressing human prostate-specific antigen (PSA): Safety and immunogenicity in a non-human primate
12. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia vires containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity
13. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine
14. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen
15. Enhancement of antitumor immunity by CTLA-4 blockade
16. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma
17. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines
18. A triad of costimulatory molecules synergize to amplify T cell activation
19. Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules
20. Construction and characterization of a triple-recombinant vaccinia vires encoding B7-1, interleukin 12, and a model tumor antigen
21. Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration
22. The future of interleukin-2: Enhancing therapeutic anticancer vaccines
23. Interleukin-2: Developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity
24. Immunization with a syngeneic tumor infected with recombinant vaccinia vires expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) induces tumor regression and long-lasting systemic immunity
25. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2
26. DNA prime-canarypox boost with polycistronic hepatitis C virus (HCV) genes generates potent immune responses to HCV structural and nonstructural proteins
27. A prime-boost immunization strategy with DNA and recombinant baculovirus-expressed protein enhances protective immunogenicity of glycoprotein D of equine herpesvirus I in naive and infection-primed mice
28. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen
29. Prime-boost immunization strategies against HIV
30. Canarypox vires-based vaccines: Prime-boost strategies to induce cell-mediated and humoral immunity against HIV
31. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors
32. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses
33. Vaccination with two different vaccinia recombinant viruses: Long-term inhibition of secondary vaccination
34. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity
35. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: Long-term protection and effect of revaccination
36. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein
37. Granulocyte-macrophage colony-stimulating factor: An effective adjuvant for protein and peptide-based vaccines
38. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant
39. Quantitative analysis of CEA expression in colorectal adenocarcinoma and serum: Lack of correlation
40. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen
41. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen
42. Phase I study in cancer patients of a diversified prime and boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen responses
43. Immunization with CEA agonist epitope pulsed FLT-3L expanded dendritic cells for human immunotherapy
44. Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen
45. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen (CEA) and the B7.1 co-stimulatory molecule
46. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas
47. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine
48. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen
49. Dendritic cells pulsed with CEA peptide induce CEA-specific CTL with restricted TCR repertoire
50. Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern
51. Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model
52. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: A murine tumor model
53. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: Enhancement by simultaneous B7-1 expression
54. Colon cancer cell vaccine prepared with replication-deficient vaccinia viruses encoding B7.1 and interleukin-2 induce antitumor response in syngeneic mice
55. Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF
56. Formation of lentivirus particles by mammalian cells infected with recombinant fowlpox virus
57. Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: Application to human immunodeficiency virus type 1 env
58. Compact, synthetic, vaccinia virus early/late promoter for protein expression
59. Comparative studies of the effects of recombinant GM-CSF and GM-CSF administered via a poxvirus to enhance the concentration of antigen-presenting cells in regional lymph nodes
60. Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line
61. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine
62. A novel approach to the generation and identification of experimental hepatic metastases in a murine model
63. The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation
64. RMA/S cells present endogenously synthesized cytosolic proteins to class I-restricted cytotoxic T lymphocytes
65. + T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21
66. Regional versus systemic delivery of recombinant vaccinia virus as suicide gene therapy for murine liver metastases
67. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice
68. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen
69. Vaccination with a recombinant vaccinia vaccine containing the B7-1 co-stimulatory molecule causes no significant toxicity and enhances T cell-mediated cytotoxicity
70. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine
71. Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes
72. Restriction of vaccinia virus replication in CHO cells occurs at the stage of viral intermediate protein synthesis